{"id":"NCT03781167","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)","officialTitle":"A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-29","primaryCompletion":"2022-08-17","completion":"2022-08-17","firstPosted":"2018-12-19","resultsPosted":"2023-10-23","lastUpdate":"2023-10-23"},"enrollment":244,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease (PD)"],"interventions":[{"type":"DRUG","name":"ABBV-951","otherNames":["Foslevodopa/Foscarbidopa"]}],"arms":[{"label":"ABBV-951 Low Dose Subgroup","type":"EXPERIMENTAL"},{"label":"ABBV-951 High Dose Subgroup","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to assess the safety and tolerability of ABBV-951 (Foslevodopa/Foscarbidopa) in participants with Parkinson's disease (PD).\n\nThis was a single-arm study with preplanned analyses conducted by dose subgroup (Low Dose or High Dose) based on the modal total daily dose (most frequent dose) over the treatment period.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"From first dose of study drug until 30 days following last dose of study drug (up to 480 days)","effectByArm":[{"arm":"ABBV-951 Low Dose Subgroup","deltaMin":121,"sd":null},{"arm":"ABBV-951 High Dose Subgroup","deltaMin":109,"sd":null},{"arm":"ABBV-951 All Participants","deltaMin":230,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":65,"countries":["United States","Australia","Belgium","Canada","Denmark","Germany","Italy","Japan","Netherlands","Russia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["38465885","37632656"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":131},"commonTop":["INFUSION SITE ERYTHEMA","INFUSION SITE NODULE","INFUSION SITE OEDEMA","INFUSION SITE CELLULITIS","FALL"]}}